OBJECTIVES: Although the discovery of phosphodiesterases (PDEs) was made soon after
the identification of cyclic adenosine monophosphate nearly half a century ago, their true …

Importance to the field: Since sildenafil was introduced 10 years ago, highly selective
phosphodiesterase type 5 inhibitors (PDE5i) have changed the medical management of …

The advent of sildenafil in 1998 represented the first revolution in the treatment of erectile
dysfunction. In February 1994 I had the opportunity to evaluate preliminary data from …

The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors
is getting wider in the last years. This review study focuses on the potential employment of …

J Clin Hypertens (Greenwich). 2012; 14: 644–649.© 2012 Wiley Periodicals, Inc.
Phosphodiesterase 5 (PDE‐5) inhibitors are selective blockers of PDE‐5, which catalyzes …

Phosphodiesterase type 5 (PDE5) is one member of a superfamily of cyclic nucleotide
hydrolyzing enzymes that specifically cleaves cyclic guanosine monophosphate (cGMP), a …

The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many
normal physiological functions and the pathophysiology of several diseases. Since the …

INTRODUCTION AND OBJECTIVES: To systematically analyze and review the available
evidence about the potential role of chronic administration of phosphodiesterase type 5 …

Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in
South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat …

Aims To review recent (since 2007) developments on the utilization of PDE5I in clinical
practice. The focus of this manuscript is on the use of PDE5I for sexual concerns. Also …